c suite ey_pharma_3.0_2016

Pharma 3.0C-Suite series, March 22nd 2016

Frank KumliEmail: [email protected]: @frankkumli

Digital medicine's march on chronic disease Nature Biotechnology 34, 239–246 (2016) http://www.nature.com/

http://www.apple.com/pr/library/2016/03/21Apple-Advances-Health-Apps-with-CareKit.html

http://www.alivecor.com//

http://www.nemauramedical.com/

https://www.veritasgenetics.com/

http://mobihealthnews.com/content/novartis-signs-aetna-cigna-pay-performance-drug-deal-no-remote-monitoring-yet

Health outcomesHealth outcomes as currency for health care systems

Value mining► Value-based P&R► Comparative

effectiveness► Risk-sharing

agreements

Consumerism► Health literacy► Empowerment

Health IT► Digital data► Social data► Mobile health

Health care reform► Access► Rebates/discounts► Value-based approach► Health IT

Healthoutcomes

Business model transformationFrom products to outcomes

Driversofchange

BusinessModelsValueproposition

Customer

► R&Dproductivity

► Patent cliff► Globalization► Demographics► Pricing & reim-

bursement

► Health carereform

► Health IT► Consumerism► Value mining

BlockbusterDrugs

DiversifiedDrugs Portfolio

HealthOutcomesPharma

1.0

PhysicianPaye

rPatie

nt

Pharma2.0

Pharma 3.0

Patient centricityInnovate the industry model around the patient

Example 1: Pfizer

Optimizing adherence§ SMS reminder service for

patients on Lipitor, guiding themto a partner pharmacy in theirneighborhood

§ Providers offer the service topatients & collect their consent

§ Patients are directed to«Partner Pharmacies» in theirneighborhood

§ Telecom provider sendsreminder SMS towards the endof each cycle

Example 2: J&J JHI

Building non-corecapabilities

• Business-unit dedicated tohealth services

• Top-down strategic decision tofoster collaborative approachesto Healthcare delivery

• Desicated unit dedicated toinnovation and not to corporatesocial responsibility

• First Life Sciences moveradvantage

Example 3: Kaiser-Permanente

Optimizing Outcomes§ Integrated payor & provider§ Very high electronic data

transparency for allstakeholders

§ Complete «healthmanagement» for patients

§ Targeted investments inprevention, e.g. standardprophylactic bone marrow scansfor post-menopausal women

§ Collaborations with pharmacompanies in clinical andmedical studies

New Business ModelsFive success factors

Connect with usDownload our reports at ey.com/VitalSigns

Firepower fireworksDrivers ofbiopharma M&A

Beyond borders2015Global biotech reportReaching new heights

Pulse of the industry2015Medical technology report

How fit is your capitalallocation strategy?Voyage to value

Dr. Frank KumliEY Life Sciences

[email protected]

Ernst & Young

Assurance | Tax | Transactions | Advisory

About Ernst & YoungErnst & Young is a global leader in assurance, tax,transaction and advisory services. Worldwide, our 167,000people are united by our shared values and an unwaveringcommitment to quality. We make a difference by helpingour people, our clients and our wider communities achievetheir potential.

Ernst & Young refers to the global organization of memberfirms of Ernst & Young Global Limited, each of which is aseparate legal entity. Ernst & Young Global Limited, a UKcompany limited by guarantee, does not provide servicesto clients. For more information about our organization,please visit www.ey.com.

Ernst & Young LLP is a client-serving member firm ofErnst & Young Global Limited operating in the US.

© 2016 Ernst & Young LLP.All Rights Reserved.

1303-1040958 _West